IDiyas

For the Inventor, By the Inventor

Titusville, NJ, United States of America

Soong-Hoon Kim

USPTO Granted Patents = 44 

 

 

Average Co-Inventor Count = 4.2

ph-index = 13

Forward Citations = 514(Granted Patents)


Location History:

  • Plainsboro, NJ (US) (2000 - 2002)
  • Lawrenceville, NJ (US) (2001 - 2013)
  • Titusville, NJ (US) (2004 - 2022)

Company Filing History:

goldMedal44 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents

Years Active: 2000-2022

Loading Chart...
Loading Chart...
Loading Chart...
44 patents (USPTO):Explore Patents
1. 11370785 - Multicyclic compounds as farnesoid X receptor modulators (2022-06-28),
2. 10889565 - 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists (2021-01-12),
3. 10392347 - 2,4-dihydroxy-nicotinamides as APJ agonists (2019-08-27),
4. 10336739 - 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists (2019-07-02),
5. 10173991 - Sulfone amide linked benzothiazole inhibitors of endothelial lipase (2019-01-08),
6. 10011594 - 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists (2018-07-03),
7. 9427442 - Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds (2016-08-30),
8. 9371328 - Imidazopyridazinecarbonitriles useful as kinase inhibitors (2016-06-21),
9. 9169240 - Ketone linked benzothiazole inhibitors of endothelial lipase (2015-10-27),
10. 8987314 - Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase (2015-03-24),
11. 8921542 - Epothilone derivatives (2014-12-30),
12. 8822454 - Bisfluoroalkyl-1,4-benzodiazepinone compounds (2014-09-02),
13. 8791257 - Substituted pyrrolotriazines as protein kinase inhibitors (2014-07-29),
14. 8680090 - Sulfonyl containing benzothiazole inhibitors of endothelial lipase (2014-03-25),
15. 8629136 - Bisfluoroalkyl-1,4-benzodiazepinone compounds (2014-01-14),

Title: The Innovative Contributions of Soong-Hoon Kim

Introduction: Soong-Hoon Kim is a distinguished inventor based in Titusville, NJ, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 44 patents, Kim has made strides in developing compounds that target crucial receptors in the human body, paving the way for new treatments for various diseases.

Latest Patents: One of Kim's most recent inventions includes the development of multicyclic compounds that act as farnesoid X receptor (FXR) modulators. This invention entails compounds of Formula (I) which can effectively modulate FXR activity, serving as potential agonists. These compounds have the potential to revolutionize treatment for conditions associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. Additionally, Kim has introduced 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists. These compounds, defined by Formula (I) in his patent, present promising medicinal properties and could be pivotal in future therapeutic applications.

Career Highlights: Kim is currently associated with Bristol-Myers Squibb Company, a leading global biopharmaceutical company dedicated to discovering and developing innovative medicines. His work within this esteemed organization showcases his commitment to advancing medical science and patient care.

Collaborations: Throughout his career, Soong-Hoon Kim has collaborated with notable colleagues, including Gregory D. Vite and James A. Johnson. These collaborations have enabled the pooling of diverse expertise, further enhancing the impact of their shared research endeavors.

Conclusion: Soong-Hoon Kim's innovative spirit and dedication to scientific discovery continue to make a substantial impact on the pharmaceutical landscape. With numerous patents and groundbreaking inventions, he remains a significant figure in the ongoing quest for improved therapies and health solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…